Medicare Enrolled
Dr. Evan Shelby, MD
Gastroenterology · Lancaster, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shelby from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shelby?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shelby
Dr. Evan Shelby is a gastroenterology specialist in Lancaster, PA, with 13 years of NPI registration. Based on federal Medicare data, Dr. Shelby performed 5,211 Medicare services across 685 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shelby received a total of $4,731 from 32 pharmaceutical and/or device companies across 247 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shelby is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice
▲ Top 4% volume in PA
$4,731 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,211
Medicare services
Top 4% in PA for gastroenterology
685
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~401 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
4,500 | $16 | $52 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
98 | $88 | $270 |
| Colon polyp removal with endoscopic snare This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination. |
93 | $199 | $1,025 |
| Colonoscopy with biopsy A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease. |
92 | $101 | $875 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
67 | $67 | $186 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
59 | $100 | $240 |
| Upper GI endoscopy with biopsy A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities. |
54 | $79 | $645 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
46 | $110 | $410 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
32 | $38 | $85 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
31 | $61 | $120 |
| Upper endoscopy (EGD) A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope. |
23 | $73 | $530 |
| Colonoscopy for colorectal cancer screening, high risk A colonoscopy performed to screen for colorectal cancer in individuals identified as being at high risk for the disease. |
23 | $175 | $750 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
22 | $70 | $270 |
| Dilation of esophagus | 17 | $31 | $210 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
16 | $45 | $259 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
13 | $95 | $301 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
13 | $20 | $101 |
| Colonoscopy for colorectal cancer screening A colonoscopy performed to screen for colorectal cancer in individuals who are not at high risk for the disease. |
12 | $161 | $750 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
86.9% high complexity
4.2% medium
8.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,731
Total received (2018-2024)
Avg $676/year across 7 years
Top 33% in PA for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
32
Companies
247
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,731 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$844
2023
$1,770
2022
$1,381
2021
$346
2020
$83
2019
$174
2018
$133
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$412
Janssen Biotech, Inc.
$73
Celgene Corporation
$54
Takeda Pharmaceuticals U.S.A., Inc.
$49
Ardelyx, Inc.
$41
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$38
PFIZER INC.
$38
Madrigal Pharmaceuticals
$30
Lilly USA, LLC
$21
Ipsen Biopharmaceuticals, Inc
$21
Mallinckrodt Hospital Products Inc.
$19
Boston Scientific Corporation
$18
IRONWOOD PHARMACEUTICALS, INC
$15
AIMMUNE THERAPEUTICS, INC.
$15
Top 3 companies account for 63.8% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$874
AbbVie Inc.
$691
Takeda Pharmaceuticals U.S.A., Inc.
$580
Celgene Corporation
$393
Janssen Biotech, Inc.
$351
PFIZER INC.
$273
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$212
GENZYME CORPORATION
$187
AbbVie, Inc.
$174
Regeneron Healthcare Solutions, Inc.
$134
Boehringer Ingelheim Pharmaceuticals, Inc.
$115
Ardelyx, Inc.
$106
Gilead Sciences, Inc.
$85
QOL Medical, LLC
$62
INTERCEPT PHARMACEUTICALS, INC.
$50
Ironwood Pharmaceuticals, Inc
$46
Amgen Inc.
$41
Merck Sharp & Dohme LLC
$40
Fresenius Kabi USA, LLC
$39
Nestle HealthCare Nutrition Inc.
$39
NESTLE HEALTHCARE NUTRITION INC.
$33
Madrigal Pharmaceuticals
$30
Lilly USA, LLC
$21
Ipsen Biopharmaceuticals, Inc
$21
Ferring Pharmaceuticals Inc.
$19
Mallinckrodt Hospital Products Inc.
$19
E.R. Squibb & Sons, L.L.C.
$19
Boston Scientific Corporation
$18
IRONWOOD PHARMACEUTICALS, INC
$15
Intercept Pharmaceuticals, Inc.
$15
AIMMUNE THERAPEUTICS, INC.
$15
Evoke Pharma, Inc.
$12
Top 3 companies account for 45.3% of all-time payments
Associated products mentioned in payments ›
AMJEVITA · CRE PRO · CREON · CYLTEZO · Creon · DIFICID · DUPIXENT · ENTYVIO · EOHILIA · Entyvio · GATTEX · GIMOTI · HUMIRA · Humira · IBSRELA · IDACIO · IQIRVO · LINZESS · Linzess · MAVYRET · MOTEGRITY · Mavyret · OCALIVA · OMVOH · REBYOTA · REMICADE · RESMETIROM · RINVOQ · SKYRIZI · STELARA · SUCRAID · Sucraid · TERLIVAZ · VELSIPITY · VIBERZI · XELJANZ · XIFAXAN · ZENPEP · ZEPOSIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Gastroenterologists within 10 mi
95
Per 100K population
17.1
County median income
$83,703
Nearest hospital
PENN STATE HEALTH LANCASTER MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Shelby is a mixed practice specialist, with above-average Medicare volume (top 4% in PA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Shelby experienced with vedolizumab infusion (entyvio)?
Based on Medicare claims data, Dr. Shelby performed 4,500 vedolizumab infusion (entyvio) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shelby receive payments from pharmaceutical companies?
Yes. Dr. Shelby received a total of $4,731 from 32 companies across 247 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shelby's costs compare to other gastroenterologists in Lancaster?
Dr. Shelby's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shelby) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Gastroenterology
Common procedures, typical costs, and what industry payments mean in gastroenterology.
Same specialty & city
Gastroenterologists in Lancaster
Browse gastroenterologists in Lancaster ranked by procedure volume and transparency data.
Highest volume
Top Gastroenterologists in PA
Gastroenterologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Gastroenterologists in PA
Which PA gastroenterologists receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology